NCT04008797 2026-03-24A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid TumorEisai Inc.Phase 1/2 Active not recruiting301 enrolled
NCT04300556 2026-03-13A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesEisai Inc.Phase 1/2 Recruiting182 enrolled
NCT05620134 2024-10-15Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic CancerSalubris Biotherapeutics IncPhase 1/2 Active not recruiting263 enrolled
NCT02501096 2023-07-20A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid TumorsEisai Inc.Phase 1/2 Completed357 enrolled 28 charts 2 FDA
NCT02432274 2023-07-11Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With OsteosarcomaEisai Inc.Phase 1/2 Completed117 enrolled 32 charts